Opinion on Cardiovascular Diseases in North America

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Statins: can the third generation make an impression?

In November 2002 Crestor, AstraZeneca's third generation statin, received its first approval, marking the arrival of the new "superstatins" and illustrating the new threat to the current market leaders Pfizer and Merck & Co. However, this new generation of dyslipidemia treatments may not be as successful as earlier launched products and may suffer from the maturing nature of the market.

Published By Datamonitor
10 Jan 2003
CommentWire
CommentWire

Alteon: sales of ALT-711 set to soar

Positive preliminary results indicate that Alteon's ALT-711 may be beneficial in treating patients with diastolic heart failure, as well as the underlying pathology of a number of diseases. ALT-711 is being targeted at areas of high unmet need with rapidly growing patient populations, a powerful combination that should see sales hit $1.3bn in 2010, just three years after launch.

Published By Datamonitor
23 Jan 2003
CommentWire
CommentWire

Merck: losing ground in the cardiovascular market

Merck is rapidly losing ground in the cardiovascular market, an area that it has traditionally dominated. Patent expiries on several major products combined with increased competition have resulted in a 20% fall in its CV revenue. Meanwhile, Pfizer saw its CV sales grow by 18% in 2002 and is leaving Merck trailing.

Published By Datamonitor
03 Feb 2003
CommentWire
CommentWire

AstraZeneca: promising results for first oral anticoagulant in 50 years

The test results for AstraZeneca's new anticoagulant Exanta put the drug ahead of its 50-year-old competitor warfarin. Exanta should also be able to put up a good fight against Aventis' Lovenox, which currently dominates the post-operative venous thromboembolism market. Although the drug may have a slower start than many analysts predict, Exanta looks set for strong sales.<BR />

Published By Datamonitor
10 Apr 2003
CommentWire
CommentWire

Solvay/Biovail: too little, too late for Teveten

Although Solvay/Biovail's Teveten (eprosartan) has demonstrated benefits in isolated systolic hypertension, Solvay has been reluctant to file for this indication. The results of the most recent trial may well be too little too late now that Teveten's major competitors, such as Diovan (valsartan), are also targeting this indication.

Published By Datamonitor
21 May 2003
CommentWire
CommentWire

Medtronic: MIRACLE results for InSync ICD

The MIRACLE ICD results reveal that Medtronic's InSync ICD provides symptomatic benefits in heart failure patients without compromising ICD function. Although use of the device will be limited by cost and associated complications, technology improvements, increased physician experience and further studies can be expected to drive future use.

Published By Datamonitor
28 May 2003
CommentWire
CommentWire

Hypertension: US doctors may follow European guidelines

The latest European guidelines for the treatment of hypertension differ significantly from the US guidelines released earlier this year. Importantly, the European ones do not recommend diuretics over other drugs as a first-line treatment. This further reduces the chance of the ALLHAT results having a negative impact on the market for non-diuretic treatments.

Published By Datamonitor
12 Jun 2003
CommentWire
CommentWire

Anti-dyslipidemics: possible anti-arrhythmic action

Although implantable cardioverter defibrillators (ICDs) can help prevent sudden cardiac death, patients suffering recurrent ventricular tachyarrhythmias can continue to suffer from symptoms such as pain, anxiety and fainting. Current anti-arrhythmic drug therapy can help in the reduction of this burden, but unpleasant side effects leave the door open for a safe and efficacious alternative.

Published By Datamonitor
03 Jul 2003
CommentWire
CommentWire

AMI treatment: facilitated transfer the way ahead

The move towards a more hybrid approach of pre-treating AMI patients with GPIIb/IIIa inhibitors and/or thrombolytics prior to transfer to an interventional center presents significant opportunities for agents that can demonstrate efficacy in this setting, such as Genentech [DNA]/BI's TNKase/Metalyse (tenecteplase).

Published By Datamonitor
29 Sep 2003
CommentWire
CommentWire

Pfizer: Inspra to be a cardio blockbuster

The approval of Pfizer's [PFE] Inspra (eplerenone) for post-MI heart failure patients, based on the EPHESUS trial results, should be sufficient for use of the drug to exceed that of its less well tolerated predecessor, spironolactone. With marketing support from Pfizer, Inspra is all set for blockbuster status.

Published By Datamonitor
13 Oct 2003

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.